SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement...

SELLAS LIFE SCIENCES ANNOUNCES POSITIVE PIVOTAL PHASE 3 REGAL TRIAL DATA SHOWING IMMUNOTHERAPEUTIC CANCER VACCINE, GALINPEPIMUT-S (GPS), DEMONSTRATED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OVERALL SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA


​​​​NEW YORK, Nov 18 (Bernama) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced positive topline results from the pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, in patients with acute myeloid leukemia (AML). The pivotal trial evaluated GPS as maintenance monotherapy in patients who achieved a second or later complete remission (CR2 or later) or complete remission with insufficient platelet recovery (CRp2 or later) following second- or later-line salvage therapy and who were ineligible for, or unable to undergo, allogeneic stem cell transplantation.

The REGAL trial met its primary endpoint of overall survival (OS), with GPS demonstrating a statistically significant and clinically meaningful improvement in OS compared with investigator’s choice of best available treatment (BAT). In the trial, GPS showed a 41% reduction in the risk of death (hazard ratio of 0.59) and a two-sided p=0.035 with a median OS of 24.0 months among GPS-treated patients versus 14.7 months with BAT.

For full news, click here